Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Capital Expenditures (2018 - 2025)

Skinvisible's Capital Expenditures history spans 7 years, with the latest figure at -$1.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures changed N/A year-over-year to -$1.0; the TTM value through Sep 2025 reached -$1.0, down 100.01%, while the annual FY2024 figure was $9218.0, 1.23% down from the prior year.
  • Capital Expenditures for Q3 2025 was -$1.0 at Skinvisible, roughly flat from -$1.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $20414.0 in Q2 2021 and bottomed at -$1.0 in Q3 2023.
  • The 4-year median for Capital Expenditures is $525.0 (2022), against an average of $4388.7.
  • The largest YoY upside for Capital Expenditures was 47.9% in 2021 against a maximum downside of 48.28% in 2021.
  • A 4-year view of Capital Expenditures shows it stood at $20414.0 in 2021, then crashed by 97.43% to $525.0 in 2022, then plummeted by 100.19% to -$1.0 in 2023, then changed by 0.0% to -$1.0 in 2025.
  • Per Business Quant, the three most recent readings for SKVI's Capital Expenditures are -$1.0 (Q3 2025), -$1.0 (Q3 2023), and $8809.0 (Q2 2023).